Overcoming multidrug resistance (MDR) in cancer by nanotechnology

Science China Chemistry

Volumn 53, Issue 11, 2010, Pages 2226-2232

  Bu, Huihui ^a   Gao, Yu ^a   Li, Yaping ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

cancer; chemotherapeutic drugs; drug delivery system; multidrug resistance; nanoparticles; nanotechnology

Indexed keywords

ANTITUMOR DRUGS; CANCER; CHEMOTHERAPEUTIC DRUGS; CONTROL RELEASE; DRUG DELIVERY SYSTEM; MULTIDRUG RESISTANCE; TARGET SITES;

DRUG DELIVERY; NANOPARTICLES;

NANOTECHNOLOGY;

EID: 78649346212     PISSN: 16747291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11426-010-4142-5     Document Type: Review

References (77)

1. Boyle P, Levin B. World cancer report: World Health Organization. 2008
2. Y.A. Luqmani 2005 Mechanisms of drug resistance in cancer chemotherapy Med Princ Pract 14 35 48 10.1159/000086183
3. R. Singh J.W. Lillard Jr 2009 Nanoparticle-based targeted drug delivery. Experimental and molecular pathology Exp Mol Pathol 86 215 223 1:CAS:528:DC%2BD1MXlslWhtrs%3D 10.1016/j.yexmp.2008.12.004
4. Z. Xu L. Chen W. Gu Y. Gao L. Lin Z. Zhang Y. Xi Y. Li 2009 The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma Biomaterials 30 226 232 10.1016/j.biomaterials.2008.09. 014
5. Q. He Z. Zhang Y. Gao J. Shi Y. Li 2009 Intracellular localization and cytotoxicity of mesoporous silica spherical nano-/micro-particles Small 5 2722 2729 1:CAS:528:DC%2BD1MXhsFektb3M 10.1002/smll.200900923
6. Y. Gao L.L. Chen W.W. Gu Y. Xi L.P. Lin Y.P. Li 2008 Targeted nanoassembly loaded with docetaxel improves intracellular drug delivery and efficacy in murine breast cancer model Mol Pharmceutics 5 1044 1054 1:CAS:528:DC%2BD1cXht1ahs7jK 10.1021/mp800072e
7. Z. Xu W. Gu J. Huang H. Sui Z. Zhou Y. Yang Z. Yan Y. Li 2005 In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery Int J Pharm 288 361 368 1:CAS:528:DC%2BD2cXhtFGhurvF 10.1016/j.ijpharm.2004.10.009
8. Z. Xu Z. Zhang Y. Chen L. Chen L. Lin Y. Li 2010 The characteristics and performance of a multifunctional nanoassembly system for the co-delivery of docetaxel and iSur-pDNA in a mouse hepatocellular carcinoma model Biomaterials 31 916 922 1:CAS:528:DC%2BD1MXhsVyisrfO 10.1016/j.biomaterials.2009.09.103
9. M. Susa A.K. Iyer K. Ryu F.J. Hornicek H. Mankin M.M. Amiji Z. Duan 2009 Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma BMC Cancer 9 399 10.1186/1471-2407-9-399
10. Y. Matsumura H. Maeda 1986 A new concept of macromolecular therapies in cancer chemotherapy: mechanism of tumor tropic accumulation of proteins and the antitumor agent SMANCS Cancer Res 6 6387 6392
11. S. Hu-Lieskovan J.D. Heidel D.W. Bartlett M.E. Davis T.J. Triche 2005 Sequence-specific knockdown of EWS-FLI1 by targeted, non-viral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic ewing's sarcoma Cancer Res 65 8984 8992 1:CAS:528:DC%2BD2MXhtVKiu7rI 10.1158/0008-5472.CAN-05-0565
12. J.I. Fletcher M. Haber M.J. Henderson M.D. Norris 2010 ABC transporters in cancer: more than just drug efflux pumps Nat Rev Cancer 10 147 156 1:CAS:528:DC%2BC3cXlvFGlsQ%3D%3D 10.1038/nrc2789
13. G. Szakács J.K. Paterson J.A. Ludwig C. Booth-Genthe M.M. Gottesman 2006 Targeting multidrug resistance in cancer Nat Rev Drug Discov 5 219 234 10.1038/nrd1984
14. L.W. Chinn D.L. Kroetz 2007 ABCB1 pharmacogenetics: progress, pitfalls, and promise Clin Pharmacol Ther 81 265 269 1:CAS:528:DC%2BD2sXisFyrtbY%3D 10.1038/sj.clpt.6100052
15. S.V. Ambudkar S. Dey C.A. Hrycyna M. Ramachandra I. Pastan M.M. Gottesman 1999 Biochemical, cellular, and pharmacological aspects of the multidrug transpoter Annu Rev Pharmacol Toxicol 39 361 398 1:CAS:528:DyaK1MXjtVejtLo%3D 10.1146/annurev.pharmtox.39.1.361
16. K. Pleban G.F. Ecker 2005 Inhibitors of P-glycoprotein lead identification and optimisation Mini Rev Med Chem 5 153 163 1:CAS:528: DC%2BD2MXhsVKmsLk%3D
17. K.W. Scotto 2003 Transcriptional regulation of ABC drug transporters Oncogene 22 7496 7511 1:CAS:528:DC%2BD3sXotlaju7s%3D 10.1038/sj.onc.1206950
18. T.J. Raub 2006 P-glycoprotein recognition of substrates and circumvention through rational drug design Mol Pharm 3 3 25 1:CAS:528:DC%2BD2MXhtlagu7%2FP 10.1021/mp0500871
19. H.L. Wong R. Bendayan A.M. Rauth H.Y. Xue K. Babakhanian X.Y. Wu 2006 A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system J Pharmacol Exp Ther 317 1372 1381 1:CAS:528:DC%2BD28Xlt1equ78%3D 10.1124/jpet.106.101154
20. X. Pepin L. Attali C. Domrault S. Gallet J.M. Metreau Y. Reault P.J. Cardot M. Imalalen C. Dubernet E. Soma P. Couvreur 1997 On the use of ion-pair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level J Chromatogr B Biomed Sci Appl 702 181 191 1:CAS:528:DyaK2sXntlCgsro%3D 10.1016/S0378-4347(97)00362-9
21. C. Vauthier C. Dubernet C. Chauvierre I. Brigger P. Couvreur 2003 Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles J Control Release 93 151 160 1:CAS:528:DC%2BD3sXovFGju74%3D 10.1016/j.jconrel.2003.08.005
22. Y. Wang L. Yu L. Han X. Sha X. Fang 2007 Di-functional Pluronic copolymer micelles for paclitaxel delivery: Synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines Int J Pharm 337 63 73 1:CAS:528:DC%2BD2sXlsFagsb8%3D 10.1016/j.ijpharm. 2006.12.033
23. E.S. Lee K. Na Y.H. Bae 2005 Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor J Control Release 103 405 418 1:CAS:528:DC%2BD2MXitV2hsbY%3D 10.1016/j.jconrel.2004.12.018
24. D. Kim E.S. Lee K. Park I.C. Kwon Y.H. Bae 2008 Doxorubicin loaded pH-sensitive micelle: anti-tumoral efficacy against ovarian A2780/DOXR tumor Pharm Res 25 2074 2082 1:CAS:528:DC%2BD1cXps1ajt70%3D 10.1007/s11095-008-9603-6
25. D. Kim Z.G. Gao E.S. Lee Y.H. Bae 2009 In vivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer Mol Pharm 6 1353 1362 1:CAS:528:DC%2BD1MXnsVOltLk%3D 10.1021/mp900021q
26. K.T. Oh E.S. Lee D. Kim Y.H. Bae 2008 l-Histidine-based pH-sensitive anticancer drug carrier micelle: Reconstitution and brief evaluation of its systemic toxicity Int J Pharm 358 177 183 1:CAS:528:DC%2BD1cXmsFagtL0%3D 10.1016/j.ijpharm.2008.03.003
27. T. Kobayashi T. Ishida Y. Okada S. Ise H. Harashima H. Kiwada 2007 Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein- mediated drug resistant tumor cells Int J Pharm 329 94 102 1:CAS:528: DC%2BD28XhtlCmtLbF 10.1016/j.ijpharm.2006.08.039
28. G. Mohajer E.S. Lee Y.H. Bae 2007 Enhanced intercellular retention activity of novel pH-sensitive polymeric micelles in wild and multidrug resistant MCF-7 cells Pharm Res 24 1618 1627 1:CAS:528:DC%2BD2sXosVKgtrs%3D 10.1007/s11095-007-9277-5
29. D. Kim E.S. Lee K.T. Oh Z.G. Gao Y.H. Bae 2008 Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH Small 4 2043 2050 1:CAS:528: DC%2BD1cXhsVKitbjP 10.1002/smll.200701275
30. E.S. Lee Z. Gao D. Kim K. Park I.C. Kwon Y.H. Bae 2008 Super pH-sensitive multifunctional polymeric micelle for tumor pHe specific TAT exposure and multidrug resistance J Control Release 129 228 236 1:CAS:528: DC%2BD1cXovFOmsrY%3D 10.1016/j.jconrel.2008.04.024
31. X.R. Song Z. Cai Y. Zheng G. He F.Y. Cui D.Q. Gong S.X. Hou S.J. Xiong X.J. Lei Y.Q. Wei 2009 Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles Eur J Pharm Sci 37 300 305 1:CAS:528:DC%2BD1MXms1Oks7g%3D 10.1016/j.ejps.2009.02.018
32. H.L. Wong R. Bendayan A.M. Rauth X.Y. Wu 2006 Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer J Control Release 116 275 284 1:CAS:528:DC%2BD28Xht1KitL%2FM 10.1016/j.jconrel.2006.09.007
33. Y. Patil T. Sadhukha L. Ma J. Panyam 2009 Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance J Control Release 136 21 29 1:CAS:528:DC%2BD1MXlvFGjt7c%3D 10.1016/j.jconrel.2009.01.021
34. A. Z. Fire 2007 Gene silencing by double-stranded RNA Cell Death Differ 14 1998 2012 1:CAS:528:DC%2BD2sXhtlajs7jK 10.1038/sj.cdd.4402253
35. C.C. Mello D. Conte Jr. 2004 Revealing the world of RNA interference Nature 431 338 342 1:CAS:528:DC%2BD2cXnsFaiu7k%3D 10.1038/nature02872
36. T. Faltus J. Yuan B. Zimmer A. Krämer S. Loibl M. Kaufmann K. Strebhardt 2004 Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells Neoplasia 6 786 795 1:CAS:528:DC%2BD2MXhtFWnsb8%3D 10.1593/neo.04313
37. S. Oliveira M.M. Fretz A. Høgset G. Storm R.M. Schiffelers 2007 Photochemical internalization enhances silencing of epidermal growth factor receptor through improved endosomal escape of siRNA Biochim Biophys Acta 1768 1211 1217 1:CAS:528:DC%2BD2sXkt1ejs7k%3D 10.1016/j.bbamem.2007.01.013
38. R.M. Schiffelers A. Ansari J. Xu Q. Zhou Q. Tang G. Storm G. Molema P.Y. Lu P.V. Scaria M.C. Woodle 2004 Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle Nucleic Acids Res 32 149 10.1093/nar/gnh140
39. J. Hua D.G. Mutch T.J. Herzog 2005 Stable suppression of MDR- 1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line Gynecol Oncol 98 31 38 1:CAS:528:DC%2BD2MXlt1Ggtb4%3D 10.1016/j.ygyno.2005.03.042
40. E.B. Logashenko A.V. Vladimirova M.N. Repkova A.G. Venyaminova E.L. Chernolovskaya V.V. Vlassov 2004 Silencing of MDR 1 gene in cancer cells by siRNA Nucleosides Nucleotides Nucleic Acids 23 861 866 1:CAS:528: DC%2BD2cXot1ahsbs%3D 10.1081/NCN-200026032
41. X.B. Xiong H. Uludaǧ A. Lavasanifar 2009 Biodegradable amphiphilic poly(ethylene oxide)-block-polyesters with grafted polyamines as supramolecular nanocarriers for efficient siRNA delivery Biomaterials 30 242 253 1:CAS:528:DC%2BD1cXht1yrsLfK 10.1016/j.biomaterials.2008.09.025
42. S. Yadav L.E. van Vlerken S.R. Little M.M. Amiji 2009 Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells Cancer Chemother Pharmacol 63 711 722 1:CAS:528:DC%2BD1MXhtVegs7Y%3D 10.1007/s00280-008-0790-y
43. 4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cells Int J Nanomedicine 4 209 216 1:CAS:528:DC%2BD1MXhsVKjsrvO 10.2147/IJN.S7090
44. R. Li R. Wu L. Zhao M. Wu L. Yang H. Zou 2010 P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells ACS Nano 4 1399 1408 1:CAS:528:DC%2BC3cXhvVKhs7c%3D 10.1021/nn9011225
45. R.G. Sargent M.A. Brenneman J.H. Wilson 1997 Repair of site-specific double-strand breaks in a mammalian chromosome by homologous and illegitimate recombination Mol. Cell Biol 17 267 277 1:CAS:528:DyaK2sXhtlensg%3D%3D
46. C. Arnaudeau C. Lundin T. Helleday 2001 DNA doublestrand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells J Mol Biol 307 1235 1245 1:CAS:528:DC%2BD3MXisVKnt7c%3D 10.1006/jmbi.2001.4564
47. T. Lindahl B. Demple P. Robins 1982 Suicide inactivation of the E. coli O6-methylguanine-DNA methyltransferase EMBO J 1 1359 1363 1:CAS:528: DyaL3sXkvFChug%3D%3D
48. J.M. Gao J. Ming B. He Z.W. Gu X.D. Zhang 2008 Controlled release of 9-nitro-20(S)-camptothecin from methoxy poly(ethylene glycol)-poly (D,L-lactide) micelles Biomed Mater 3 15 13 10.1088/1748-6041/3/1/015013
49. O. Khan M.R. Middleton 2007 The therapeutic potential of O6-alkylguanine DNA alkyltransferase inhibitors Expert Opin Investig Drugs 16 1573 1584 1:CAS:528:DC%2BD2sXhtFekt7rN 10.1517/13543784.16.10.1573
50. T. Helleday E. Petermann C. Lundin B. Hodgson R.A. Sharma 2008 DNA repair pathways as targets for cancer therapy Nat Rev Cancer 8 193 204 1:CAS:528:DC%2BD1cXitlOisr8%3D 10.1038/nrc2342
51. G. Bhabra A. Sood B. Fisher L. Cartwright M. Saunders W.H. Evans A. Surprenant G. Lopez-Castejon S. Mann S.A. Davis L.A. Hails E. Ingham P. Verkade J. Lane K. Heesom R. Newson C.P. Case 2009 Nanoparticles can cause DNA damage across a cellular barrier Nat Nanotechnol 4 876 883 1:CAS:528:DC%2BD1MXhsFagsrjI 10.1038/nnano.2009.313
52. B. Kang M.A. Mackey M.A. El-Sayed 2010 Nuclear targeting of gold nanoparticles in cancer cells induces DNA damage, causing cytokinesis arrest and apoptosis J Am Chem Soc 132 1517 1519 1:CAS:528:DC%2BC3cXnvFSqtg%3D%3D 10.1021/ja9102698
53. E. Porcel S. Liehn H. Remita N. Usami K. Kobayashi Y. Furusawa C. Le Sech S. Lacombe 2010 Platinum nanoparticles: A promising material for future cancer therapy? Nanotechnology 21 85103 10.1088/0957-4484/21/8/085103
54. P.V. Asharani N. Xinyi M.P. Hande S. Valiyaveettil 2010 DNA damage and p53-mediated growth arrest in human cells treated with platinum nanoparticles Nanomedicine (Lond) 5 51 64 1:CAS:528:DC%2BD1MXhs1Sjs7%2FP 10.2217/nnm.09.85
55. Foldbjerg R, Dang DA, Autrup H. Cytotoxicity and genotoxicity of silver nanoparticles in the human lung cancer cell line, A549. Arch Toxicol, 2010, DOI 10.1007/s00204-010-0545-5
56. B. Trouiller R. Reliene A. Westbrook P. Solaimani R.H. Schiestl 2009 Titanium dioxide nanoparticles induce DNA damage and genetic instability in vivo in mice Cancer Res 69 8784 8789 1:CAS:528:DC%2BD1MXhtl2rtr7E 10.1158/0008-5472.CAN-09-2496
57. A. Degterev M. Boyce J. Yuan 2003 A decade of caspases Oncogene 22 8543 8567 1:CAS:528:DC%2BD3sXptFOmtbg%3D 10.1038/sj.onc.1207107
58. D.S. Ziegler A.L. Kung M.W. Kieran 2008 Anti-apoptosis mechanisms in malignant gliomas J Clin Oncol 26 493 500 1:CAS:528:DC%2BD1cXitVGnu7w%3D 10.1200/JCO.2007.13.9717
59. K.M. Debatin 1999 The role of the CD95 system in chemotherapy Drug Resist Updat 2 85 90 1:CAS:528:DyaK1MXktVSrsrY%3D 10.1054/drup.1999.0073
60. I. Herr K.M. Debatin 2001 Cellular stress response and apoptosis in cancer therapy Blood 98 2603 2614 1:CAS:528:DC%2BD3MXotVegs7o%3D 10.1182/blood.V98.9.2603
61. K.M. Debatin 1997 Anticancer drugs, programmed cell death and the immune system: defining new roles in an old play J Natl Cancer Inst 89 750 753 1:CAS:528:DyaK2sXktVClsrs%3D 10.1093/jnci/89.11.750
62. S.H. Kaufmann W.C. Earnshaw 2000 Induction of apoptosis by cancer chemotherapy Exp Cell Res 256 42 49 1:CAS:528:DC%2BD3cXitVajsLg%3D 10.1006/excr.2000.4838
63. E. Solary N. Droin A. Bettaieb L. Corcos M.T. Dimanche-Boitrel C. Garrido 2000 Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies Leukemia 14 1833 1849 1:CAS:528: DC%2BD3cXnslWgtr0%3D 10.1038/sj.leu.2401902
64. S.W. Lowe A.W. Lin 2000 Apoptosis in cancer Carcinogenesis 21 485 495 1:CAS:528:DC%2BD3cXitVeitro%3D 10.1093/carcin/21.3.485
65. S.H. Kaufmann G.J. Gores 2000 Apoptosis in cancer: cause and cure Bioessays 22 1007 1017 1:CAS:528:DC%2BD3MXmslShsrs%3D 10.1002/1521-1878(200011) 22:11<1007::AID-BIES7>3.0.CO;2-4
66. K.M. Debatin 2004 Apoptosis pathways in cancer and cancer therapy Cancer Immunol Immunother 53 153 159 10.1007/s00262-003-0474-8
67. J.M. Kuijlen J.J. Mooij I. Platteel E.W. Hoving W.T. van der Graaf M.M. Span H. Hollema W.F. den Dunnen 2006 TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme J Neurooncol 78 161 171 1:CAS:528:DC%2BD28XotFeiur4%3D 10.1007/s11060-005-9081-1
68. T. Oltersdorf S.W. Elmore A.R. Shoemaker R.C. Armstrong D.J. Augeri B.A. Belli M. Bruncko T.L. Deckwerth J. Dinges P.J. Hajduk M.K. Joseph S. Kitada S.J. Korsmeyer A.R. Kunzer A. Letai C. Li M.J. Mitten D.G. Nettesheim S. Ng P.M. Nimmer J.M. O'Connor A. Oleksijew A.M. Petros J.C. Reed W. Shen S.K. Tahir C.B. Thompson K.J. Tomaselli B. Wang M.D. Wendt H. Zhang S.W. Fesik S.H. Rosenberg O. Tilman S.W. Elmore A.R. Shoemaker R.C. Armstrong 2005 An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 435 677 681 1:CAS:528:DC%2BD2MXks1Ogtb0%3D 10.1038/nature03579
69. A.M. Chen M. Zhang D. Wei D. Stueber O. Taratula T. Minko H. He 2009 Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug resistant cancer cells Small 5 2673 2677 1:CAS:528:DC%2BD1MXhsFektb3L 10.1002/smll.200900621
70. Y. Wang S. Gao W.H. Ye H.S. Yoon Y.Y. Yang 2006 Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer Nat Mater 5 791 796 1:CAS:528:DC%2BD28XhtVWqsLvK 10.1038/nmat1737
71. T. Minko E.V. Batrakova S. Li Y. Li R.I. Pakunlu V.Y. Alakhov A.V. Kabanov 2005 Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells J Control Release 105 269 278 1:CAS:528:DC%2BD2MXlvVyrt7g%3D 10.1016/j.jconrel.2005.03.019
72. D.D. Guo H.S. Moon R. Arote J.H. Seo J.S. Quan Y.J. Choi C.S. Cho 2007 Enhanced anticancer effect of conjugated linoleic acid by conjugation with Pluronic F127 on MCF-7 breast cancer cells Cancer Lett 254 244 254 1:CAS:528:DC%2BD2sXosFKjs7Y%3D 10.1016/j.canlet.2007.03.007
73. 4 overcome multidrug resistance and induce apoptosis of K562-n/VCR cells in vivo Int J Nanomedicine 4 201 208 1:CAS:528:DC%2BD1MXhsVKjsrvN 10.2147/IJN.S7287
74. L.E. Van Vlerken Z. Duan M.V. Seiden M.M. Amiji 2007 Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer Cancer Res 67 4843 4850 10.1158/0008-5472.CAN-06-1648
75. X. Yang W. Deng L. Fu E. Blanco J. Gao D. Quan X. Shuai 2008 Folate-functionalized polymeric micelles for tumor targeted delivery of a potent multidrug-resistance modulator FG020326 J Biomed Mater Res A 86 48 60
76. R.I. Pakunlu Y. Wang M. Saad J.J. Khandare V. Starovoytov T. Minko 2006 In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug J Control Release 114 153 162 1:CAS:528:DC%2BD28XovF2ksLY%3D 10.1016/j.jconrel.2006.06.010
77. M. Saad O.B. Garbuzenko T. Minko 2008 Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer Nanomedicine (Lond) 3 761 776 1:CAS:528:DC%2BD1cXhsVKlsb3O 10.2217/17435889.3.6.761